Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2CNS 2Dermatologic 1

Conditions

Neuroendocrine Tumors 7Pheochromocytoma 2Paraganglioma 2Gastro-enteropancreatic neuroendocrine tumor 2Vipoma 1Thymus Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Meningioma 1Insulinoma 1Gastrinoma 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

3-Iodobenzylguanidine 8anlotinib 4Temozolomide 4lutetium Lu 177 dotatate 3Phenoxybenzamine 3Everolimus 3pegfilgrastim 2cabozantinib 2Granulocyte Colony-Stimulating Factor 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Adrenalectomy 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1vandetanib 1temsirolimus 1pentetreotide 1penpulimab 1pembrolizumab 1olaparib 1lenvatinib 1lanreotide 1gallium Ga 68 dotatate 1fluorodopa F 18 1fludarabine phosphate 1belzutifan 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pheochromocytoma × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT06045260 2024-08-13

LUFOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
100 enrolled
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04276597 2023-03-10

PUTNET

Excel Diagnostics and Nuclear Oncology Center

Phase 2 Withdrawn
CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡